Captozyme Accepted to the NIH Commercialization Accelerator Program (CAP)

The NIH Commercialization Accelerator Program (CAP) is designed to help some of the agency’s most promising small life science and healthcare Phase II grantees develop their commercial businesses and transition their SBIR/STTR-funded technologies into the marketplace. Applicants are selected via a competitive process for a limited number of slots in the program.

See more information here: https://sbir.nih.gov/cap